Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directionsRiccardo Gerosa, Alberto Zambelli, Rita De Sanctis et al.|Critical Reviews in Oncology/Hematology|2024Cited by 87
Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?Rosalba Torrisi, Armando Santoro, Emilia Marrazzo et al.|Critical Reviews in Oncology/Hematology|2021Cited by 63
Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?Rosalba Torrisi, Armando Santoro, Monica Zuradelli et al.|Critical Reviews in Oncology/Hematology|2019Cited by 33
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer PatientsRita De Sanctis, Armando Santoro, Elisa Agostinetto et al.|Oncology|2018Cited by 20
Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with AbemaciclibFlavia Jacobs, Rita De Sanctis, Elisa Agostinetto et al.|Journal of Clinical Medicine|2023Cited by 15